RUBINO RICHARD J, Chief Financial Officer, added 5,040 shares of Aerie Pharmaceuticals, Inc. (AERI) to its portfolio at the rate of $19.93 per share valuing $100,447 on Sep 09. The insider has now 339,446 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $21.19, with a 2nd Resistance Point sitting at $21.61. Meanwhile, this company’s stock has a 1st Support Level at $20.15 and a 2nd Support Level at $19.53. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Aerie Pharmaceuticals, Inc. (AERI) was $20.77. Aerie Pharmaceuticals, Inc. (AERI) stock has gained $2.80, or 15.55%, in the past five days. In the last full month, these shares have lost -$3.07, or -12.88%. In the past three months, this stock’s price has fallen by -$3.60, or -14.77%. This year-to-date, Aerie Pharmaceuticals, Inc. (AERI) shares have lost -$15.33, or -42.47%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Aerie Pharmaceuticals, Inc. (AERI) stock, 50% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Sell .”
With 45,939 K shares outstanding, this company currently has a market capitalization of $931,643K. Aerie Pharmaceuticals, Inc. (AERI) generates $24,180 K in annual sales, amounting to annual net income of -$232,570 K. This stock has generated a 1-Year Total Return of -64.90%, a 3-Year Total Return of -42.16%, and a 5-year Total Return of -11.32%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 06/19, Aerie Pharmaceuticals, Inc. (AERI) reported earnings of -$0.80 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.87 per share, representing a 0.07 difference and 8.05% surprise. In the previous quarter ending in 03/19, the reported earnings of -$0.78 represented a 0.13 difference from the consensus estimate calling for -$0.91 per share, which was a 14.29% surprise.
For the current fiscal quarter, which is set to end in 09/2019, the average earnings estimate is -$0.87 per share. This estimate came from a total of 5 Wall Street Analysts. Of those market experts, the high estimate was -$0.60 and the low estimate was -$1.10. In the year-ago quarter, Aerie Pharmaceuticals, Inc. (AERI) generated per-share earnings of -$1.73. If the analysts are correct about the current quarter’s earnings, the growth will be +49.71%.
Turning our focus now to insider trading activity, there have been 19 purchases (780,190 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 29 insider buys amounting to 851,729 shares and 3 insider sales amounting to 8,812 shares. In the past full year, 35 insider purchases were made (involving 917,587 shares) and 30 insider sell-offs equivalent to 75,215 shares.
Moving onto liquidity, Aerie Pharmaceuticals, Inc. (AERI) has a Current Ratio of 4.34, a Quick Ratio of 4.14 and a Cash Ratio of 3.99. Looking at this company’s capital structure, its Total Debt to Total Equity is 0.09, its Total Debt to Total Capital is 0.09, and its Total Debt to Total Assets is now 0.07. Looking even further ahead into the future, its Long-Term Debt to Equity is -82.87.